Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: Effects on progression and prognosis

Zeitschrift fur Gastroenterologie

Volumn 43, Issue 9, 2005, Pages 1051-1059

  Leuschner, Ulrich ^a   Manns, M P ^b   Eisebitt, R ^c  

^a GOETHE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c ClinResearch   (Germany)

Author keywords

Primary biliary cirrhosis; Survival; Therapy results; Ursodeoxycholic acid

Indexed keywords

BILIRUBIN; URSODEOXYCHOLIC ACID;

BILIRUBIN BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MATHEMATICAL MODEL; MORTALITY; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS, BILIARY; PROGNOSIS; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 25444517316     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858281     Document Type: Review

References (71)

1. Leuschner U, Fischer H, Kurtz W et al. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-1274
2. Poupon RE, Balkau B, Eschwège E et al. The UDCA-PBC-Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548-1554
3. Combes B, Carithers RL, Maddrey WC et al. A randomised double-blind placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-766
4. Czaya AJ. Autoimmune liver disease. Curr Opin Gastroenterol 1999; 15: 240-248
5. Kim WR, Lindor KD, Locke GR et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology 2000; 119: 1631-1636
6. Kingham JG, Parker DR. The association between primary biliary cirrhosis in coeliac disease: a study of relative prevalence. Gut 1998; 42: 120-122
7. Howel D, Fischbacher C, Bhopal R et al. An exploratory population based case-control study of primary biliary cirrhosis. Hepatology 2000; 31: 1055-1060
8. Prince MI, James OFW. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003; 7: 795-819
9. Scheuer PJ. Ludwig-Symposium on biliary disorders - part 2. Pathologic features and evaluation of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73: 179-183
10. Christensen E, Neuberger J, Crowe J et al. Benefical effect of azathioprine and prediction of progression in primary biliary cirrhosis. Trial results of an international trial. Gastroenterology 1985; 89: 1085-1091
11. Dickson ER, Grambsch PM, Fleming TR et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989; 10: 1-7
12. Rydning A, Schrumpf E, Abdelnoor M et al. Factor of prognostic importance in primary biliary cirrhosis. Scand J Gastroenterol 1990; 25: 119-126
13. Christensen E. Prognostic modelling in primary biliary cirrhosis. West End Studios Eastbourne BN, UK. 1999: 93-99
14. Murtaugh PA, Dickson ER, van Dam GM et al. Primary biliary cirrhosis: Prediction of short-term survival based on repeated patient visits. Hepatology 1994; 20: 126-134
15. Grambsch PM, Dickson ER, Kaplan M et al. Extramural cross validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10: 846-850
16. Klion FM, Fabry TL, Palmer M et al. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known end point. Gastroenterology 1992; 102: 310-313
17. Christensen E, Altman DG, Neuberger J et al. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993; 105: 1865-1876
18. Kim WR, Wiesner RH, Poterucha JJ et al. Adaption of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl 2000; 6: 489-494
19. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo Risk scores - where are we and where should we go? J Hepatol 2004; 41: 344-350
20. Christensen E, Schlichting P, Andersen PK et al. Updating prognosis and therapeutic effect evaluation in cirrhosis using Cox's multiple regression model for time dependent variables. Scand J Gastroenterol 1986; 21: 163-174
21. Jensen DM. Cholestasis. Clinics in Liver Disease 1999; 3: 529-570
22. Angulo P, Lindor KD, Therneau TM et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-121
23. Lindor KD, Therneau TM, Jorgensen RA et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-1518
24. Emond M, Carithers RL Jr, Luketi VA et al. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S. multicenter trial to expected survival using the Mayo clinic prognosis model. Hepatology 1996; 24: 168A
25. Markus BH, Dickson ER, Grambsch PM et al. Efficacy of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320: 1709-1713
26. Corpechot C, Carrat F, Poupon R et al. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol treated patients. Gastroenterology 2002; 122: 652-658
27. Locke III GR, Therneau TM, Ludwig J et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1998; 23: 52-56
28. Roll J, Boyer JL, Barry DL et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Eng J Med 1983; 308: 1-7
29. Goudie BM, Burt AD, MacFarlane GJ et al. Risk factors and prognosis in primary biliary cirrhosis. Am J Gastroenterol 1989; 84: 713-716
30. (erratum in Am J Gastroenterol 1989; 84: 1474)
31. Angulo P. Primary biliary cirrhosis and primary sclerosing cholangitis. Clinics in Liver Disease 1999; 3: 529-571
32. Pasha TM, Dickson ER. Survival algorithms and outcome analysis in primary biliary cirrhosis. Seminars in Liver Disease 1997; 17: 147-158
33. Parés A, Rodés J. Natural history of primary biliary cirrhosis. Clinics in Liver Disease 2003; 7: 779-794
34. Felix R, Schuster S. A new method for the measurement of itch and response to treatment. Br J Dermatol 1975; 93: 303-312
35. Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clinics in Liver Disease 2003; 7: 879-900
36. Goldblatt J, Taylor PJ, Lipman T et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002; 122: 1235-1241
37. Cauch-Dudek K, Abbey S, Stewart DE et al. Fatigue in primary biliary cirrhosis. Gut 1998; 43: 705-710
38. Kilmurry MR, Heathcote EJ, Cauch-Dudek K et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23: 1148-1153
39. Christensen E, Crowe J, Doniach D et al. Clinical pattern and course of disease in primary biliary cirrhosis based on the analysis of 236 patients. Gastroenterology 1980; 236: 46-78
40. Mahl T, Shockcor W, Boyer JL. Primary biliary cirrhosis. Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-713
41. Springer J, Cauch-Dudek K, O'Rourke K et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53
42. Prince M, Chetwynd A, Newman W et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 1044: 51-123
43. Parés A, Bruguera M, Rodés J. Cirrosis biliar. Evaluación clínica y criterios de valor pronóstico. Gastroenterol Hepatol 1981; 4: 76-81
44. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137-140
45. Perez Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu 1979; 14: 183-213
46. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124: 1599-1607
47. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313
48. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40: 860-867
49. Sobesky R, Mathurin P, Charlotte F. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-386
50. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239-242
51. Wanless IR, Wong F, Blendis LM et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247
52. Varin F, Huet PM. Hepatic microcirculation in the perfused cirrhotic rat liver. J Clin Invest 1985; 76: 1904-1912
53. Gaudio E, Pannarale L, Onori P et al. A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. Hepatology 1993; 17: 477-485
54. Corpechot C, Carrat F, Poupon R et al. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-658
55. Goulis J, Leandro G, Burrough AK. Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. The Lancet 1999; 354: 1053-1060
56. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; 1: CD 000 551
57. Papatheodoridis GV, Hadziyannis ES, Deutsch M et al. Ursodeoxycholic acid (UDCA) in primary biliary cirrhosis. Trial results of a 12-year prospective randomized, controlled trial. Amer J Gastroenterol 2002; 32: 561-566
58. Parés A, Caballeria L, Rodés J et al. Long-term effects of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. J Hepatol 2000; 32: 561-566
59. Combes B, Luketik VA, Peters MG et al. Prolonged follow-up of patients in the U.S. multicenter trial ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 264-298
60. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: Lessons from the past - issues for the future. J Hepatol 2000; 32: 685-688
61. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch, A (Pathol Anat) 1978; 379: 103-112
62. Williams CN, Al Kuawi B, Blanchard W. Bioavailability of four ursodeoxycholic acid preparations. Aliment Pharmacol Ther 2000; 14: 1133-1139
63. Schiffman ML, Kaplan GD, Brinkmann V et al. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995; 122: 899-905
64. Kjaegard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomised trials in meta-analyses. Ann Int Med 2001; 135: 982-989
65. Schulz KF, Chalmers I, Hayes R et al. Empirical evidence of bias. Dimensions of methodological quality associates with estimates of treatment of controlled trials. JAMA 1995; 273: 408-412
66. Corpechot C, Carrat F, Bonnaud AM et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-1199
67. Parés A, Caballeria L, Bruguera M et al. Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid. J Hepatol 2001; 34 (Suppl 1): 189-190
68. Parés A, Caballeria L, Rodés J. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis. J Hepatol 2001; 34 (Suppl 1): 187-188
69. Poupon RE, Lindor KD, Cauch-Dudek K et al. Combined analysis of randomised controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890
70. Poupon R, Corpechot C, Carrat F et al. Primary biliary cirrhosis: Long-term therapy with ursodeoxycholic acid. In: Leuschner U, Broomé U, Stiehl A (Hrsg). Cholestatic liver diseases. Therapeutic options and perspectives. Kluwer, Dordrecht, Boston, London, 2004: 171-178
71. Corpechot C, Carrat F, Bahr A et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297-303